Core Viewpoint - Sanwei Biotech is actively advancing the industrialization and market expansion of diversified products, including allulose, tagatose, mannitol, and others, to enhance its product structure and overall business resilience [2]. Product Development - Allulose: The company has launched a production capacity of 10,000 tons, with an additional 10,000 tons under construction. Sales from January to September have shown significant year-on-year growth, meeting the needs of domestic clients like Nayuki Tea and steadily increasing overseas demand [2]. - Tagatose: Approved as a new food ingredient in China since 2014 and recognized in multiple countries, the company is optimizing production processes to reduce costs and enhance market potential. Tagatose and allulose both possess health benefits related to blood sugar control and gut microbiota regulation, with ongoing efficacy research in collaboration with Binzhou Medical University [2]. - Mannose: The company has small-scale production capabilities and is in the process of applying for domestic and overseas certifications. Mannose is gaining attention for its applications in medical research and health nutrition [2]. - Mannitol: The company has developed a cost advantage through new production processes and plans to gradually introduce it to the market [2]. - Reb M: The market acceptance of Reb M is increasing through continuous promotion, and the company has also developed sweet tea glycosides from regular steviol glycosides, with mature processing technology [2]. - Cosmetic Ingredients: The company leverages its synthetic biology technology to develop glycerol glycosides, ascorbic acid glucosides, and alpha arbutin, expanding its product applications in the daily chemical sector [2]. Strategic Goals - The gradual advancement of these products will help the company maintain its core competitiveness in erythritol while enhancing product diversity and improving overall business stability and risk resistance [2].

证券日报网讯三元生物11月25日发布公告，在公司回答调研者提问时表示，公司围绕功能糖的产业化应 用，始终坚持以客户需求为导向，积极推进新品市场开拓。在阿洛酮糖方面，泰莱等多家美国客户对阿 洛酮糖的需求较为旺盛，澳大利亚和东南亚市场的接受度也开始增加。国内目前拥有阿洛酮糖生产许可 证并具备实际产能的厂家较少，为公司抢占市场先机创造了有利条件。塔格糖方面，日本下游企业正在 加速布局，已有客户前来公司调研产能与质量体系，以确保其终端产品的原料供应稳定性。此外，有日 本知名企业计划开发含甘露糖的食品，正在研究以公司产品为基础推动甘露糖在日本的法规注册。上述 部分合作仍处于沟通与论证阶段，公司将继续在合规前提下稳步推进新品落地。 （文章来源：证券日报） ...